Wall Street analysts forecast that Humana Inc (NYSE:HUM) will announce $13.91 billion in sales for the current quarter, Zacks reports. Seven analysts have provided estimates for Humana’s earnings, with the lowest sales estimate coming in at $13.74 billion and the highest estimate coming in at $14.12 billion. Humana posted sales of $13.19 billion in the same quarter last year, which suggests a positive year over year growth rate of 5.5%. The company is scheduled to report its next quarterly earnings results on Wednesday, February 6th.
On average, analysts expect that Humana will report full-year sales of $56.52 billion for the current financial year, with estimates ranging from $56.13 billion to $56.86 billion. For the next fiscal year, analysts forecast that the firm will post sales of $61.14 billion, with estimates ranging from $60.38 billion to $61.98 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Humana.
Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share for the quarter, beating analysts’ consensus estimates of $4.29 by $0.29. The firm had revenue of $14.21 billion for the quarter, compared to analysts’ expectations of $13.97 billion. Humana had a net margin of 2.70% and a return on equity of 19.10%. During the same period in the previous year, the company posted $3.39 earnings per share.
A number of analysts recently issued reports on HUM shares. MED lifted their price target on shares of Humana from $350.00 to $373.00 and gave the stock an “outperform” rating in a research note on Thursday, November 8th. Royal Bank of Canada boosted their price target on shares of Humana from $318.00 to $349.00 and gave the company a “sector perform” rating in a report on Thursday, November 8th. Zacks Investment Research downgraded shares of Humana from a “buy” rating to a “hold” rating in a report on Friday, October 5th. Credit Suisse Group upped their price objective on shares of Humana from $370.00 to $390.00 and gave the stock an “outperform” rating in a report on Thursday, November 8th. Finally, Bank of America boosted their price target on shares of Humana from $400.00 to $415.00 and gave the stock a “buy” rating in a research report on Thursday, November 8th. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $352.10.
Shares of HUM traded down $10.32 during mid-day trading on Tuesday, reaching $305.95. 918,708 shares of the stock traded hands, compared to its average volume of 1,062,774. The firm has a market capitalization of $44.51 billion, a P/E ratio of 26.13, a P/E/G ratio of 1.54 and a beta of 0.99. Humana has a 12-month low of $242.00 and a 12-month high of $355.88. The company has a quick ratio of 1.68, a current ratio of 1.68 and a debt-to-equity ratio of 0.45.
The company also recently declared a quarterly dividend, which will be paid on Friday, January 25th. Investors of record on Monday, December 31st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 0.65%. The ex-dividend date of this dividend is Friday, December 28th. Humana’s dividend payout ratio is 11.96%.
In related news, CEO Bruce D. Broussard sold 18,000 shares of Humana stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $328.66, for a total value of $5,915,880.00. Following the sale, the chief executive officer now owns 71,085 shares of the company’s stock, valued at approximately $23,362,796.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Roy A. Beveridge sold 4,622 shares of Humana stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $341.06, for a total value of $1,576,379.32. Following the completion of the sale, the insider now directly owns 10,621 shares in the company, valued at approximately $3,622,398.26. The disclosure for this sale can be found here. 0.60% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC raised its holdings in shares of Humana by 1.4% during the 3rd quarter. FMR LLC now owns 12,379,797 shares of the insurance provider’s stock worth $4,190,809,000 after buying an additional 167,283 shares in the last quarter. BlackRock Inc. boosted its position in shares of Humana by 1.2% during the 3rd quarter. BlackRock Inc. now owns 12,311,736 shares of the insurance provider’s stock valued at $4,167,767,000 after purchasing an additional 140,731 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Humana by 1.4% in the third quarter. Vanguard Group Inc. now owns 10,104,225 shares of the insurance provider’s stock worth $3,420,482,000 after acquiring an additional 140,864 shares in the last quarter. Capital International Investors raised its stake in shares of Humana by 3,030.3% in the third quarter. Capital International Investors now owns 8,217,296 shares of the insurance provider’s stock worth $2,781,719,000 after purchasing an additional 7,954,786 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in Humana by 14.1% in the third quarter. Renaissance Technologies LLC now owns 3,174,800 shares of the insurance provider’s stock worth $1,074,733,000 after buying an additional 391,300 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Read More: Dividend Stocks – Are They Right For You?
Get a free copy of the Zacks research report on Humana (HUM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.